Is injectable stanozolol at 50mg/ml effective specifically for a cutting cycle?

Yes — stanozolol is one of the most well-documented cutting-phase androgens because it does not aromatise to oestrogen, so no water retention blunts the visual outcome. At 50mg every other day, it supports nitrogen retention and SHBG suppression during a caloric deficit, preserving lean tissue while the body preferentially mobilises stored fat.

How do experienced athletes structure Stanabol 50 dosing across a cutting phase?

A common structure begins with a 50mg injection on day one as a loading dose, then 25–50mg every other day for weeks two through six. The 10ml vial provides enough volume to cover the full block. Dose is typically tapered or halted two to three days before cycle end to align with the compound's rapid plasma clearance.

What compounds pair well with Stanabol 50 for maximum definition without excess water retention?

Testosterone Propionate as a base keeps androgenic support high without oestrogen-driven fluid, while Trenbolone Acetate adds hardness through a non-aromatising mechanism. Both complement stanozolol's SHBG-suppressing action. All cardiovascular markers — particularly HDL measured by direct enzymatic assay — should be monitored throughout any multi-compound cutting stack.

Can Stanabol 50 be drawn accurately with an insulin syringe, and how does the 50mg/ml concentration help?

Yes. A standard 1ml insulin syringe graduated in 0.01ml units draws 0.5ml for a 25mg dose or 1.0ml for a 50mg dose from the 10ml vial — both increments sit on visible syringe markings without estimation. The 50mg/ml concentration is the lowest in this injectable stanozolol product group, offering the finest practical dose-step resolution for precise titration.

How should the Stanabol 50 10ml vial be stored after first use?

Store upright at 15–25°C away from direct light; refrigeration is not required but is acceptable. After first needle entry, use the vial within 28 days and inspect the suspension before each draw — re-shake gently to restore homogeneity if particles have settled. Discard if the suspension appears discoloured or if particulate matter does not disperse with agitation. (2) angle_used

Frontload Formula

British Dragon

Stanabol 50 50mg/ml 10ml Vial by British Dragon

Name: Stanabol 50
Brand: British Dragon
SKU: INJ-STAN-BRD-50-023
Price: 28.00 EUR
Availability: InStock

Stanabol 50 is an injectable stanozolol formulation at 50mg/ml, presented in a 10ml multi-use vial and specifically suited to cutting and body-composition refinement phases where hard, vascular musculature is the primary goal. Each millilitre delivers a precise, measurable dose without oestrogen-related water retention, making it a go-to compound during caloric-deficit training blocks. British Dragon's quality framework subjects every finished Stanabol 50 batch to reversed-phase HPLC potency verification and LAL endotoxin screening before release — two independent control gates operating under GMP-aligned manufacturing standards.

€28.00Free shipping on orders over €300

In stock

Ships within 48 h Lab-tested batch

Preserves contractile lean tissue during sustained caloric deficits
Delivers a dry, vascular aesthetic without oestrogenic water retention
Aqueous suspension clears rapidly, giving precise end-of-cycle timing control
10ml vial volume covers a full six-week every-other-day cutting block at 50mg
SHBG suppression amplifies the free bioactive fraction of co-administered testosterone base
HPLC-verified and LAL endotoxin-tested at the finished-product stage before release
50mg/ml concentration — lowest in the injectable stanozolol group — enables fine-step dose adjustment

Phase	Dosage	Note
Early cutting phase (weeks 1–2)	50mg every other day (1.0ml per injection)	Establish tissue levels rapidly; 10ml vial supplies sufficient volume for the full block
Mid cutting phase (weeks 3–5)	25–50mg every other day (0.5–1.0ml)	Adjust based on HDL monitoring (direct enzymatic assay) and tolerability
Peak-week / final week	25mg every other day or halt 48–72 hours before target date	Fast clearance (plasma half-life ~24 hours by radioimmunoassay) allows tight timing
Female athletes (definition phase)	10–15mg every other day (0.2–0.3ml)	Lowest effective dose; discontinue immediately at first signs of virilisation

Key takeaways

Target the final six to ten weeks of a cut with Stanabol 50.
Draw 0.5ml or 1.0ml directly — no fractional calculation needed.
Pair with a lean testosterone ester to maintain androgenic support without fluid.
Monitor HDL by direct enzymatic assay at baseline and mid-cycle.
Expect plasma clearance within days, enabling tight end-of-cycle control.

Stanabol 50 in Cutting and Definition Cycles

Stanabol 50 is a water-based injectable stanozolol preparation formulated at 50mg/ml and designed as a precision instrument for cutting cycles, where the objective is retaining lean contractile tissue while reducing body-fat percentage and subcutaneous water. Stanozolol suppresses sex-hormone-binding globulin through androgen receptor activation in hepatic tissue, a mechanism that elevates the bioactive free-androgen fraction circulating alongside any testosterone base without contributing oestrogenic conversion. Compared to oil-based pre-competition compounds, an aqueous stanozolol suspension clears the system significantly faster — measured plasma half-life sits near 24 hours by radioimmunoassay — which gives practitioners tighter control over end-of-cycle timing and drug-testing clearance windows.

Why the 50mg/ml Concentration Suits Cutting Protocols

The 50mg/ml concentration maps cleanly onto the dose ranges most commonly applied during caloric-deficit phases: 25mg drawn as 0.5ml or 50mg drawn as 1.0ml, with no fractional arithmetic required at injection time. Cutting-phase practitioners typically run stanozolol in the final six to ten weeks of a preparation, when compound selection prioritises nitrogen retention and hardness over mass accumulation. The 10ml vial volume covers a full six-week every-other-day protocol of roughly eighteen injections at the 50mg dose, or extends to twelve weeks at 25mg alternate-day frequency — a practical match for either a standard pre-contest block or a longer body-recomposition phase.

Stacking Within a Cutting Phase

Stanabol 50 delivers its strongest definition-phase contribution when anchored to a lean-ester testosterone base such as Testosterone Propionate, which maintains androgen support while minimising oestrogenic fluid accumulation. Trenbolone Acetate is a second common partner: both compounds are non-aromatising, so the combined androgenic stimulus operates without the subcutaneous water retention that undermines visual detail during peak week. Practitioners monitoring cardiovascular markers should note that HDL suppression is dose- and duration-dependent; lipid panels measured by direct enzymatic assay at baseline, mid-cycle, and cycle end provide the clearest picture of cumulative cardiovascular load.

Quality Control: British Dragon Stanabol 50

Each Stanabol 50 batch undergoes two-gate release testing: HPLC quantification confirms active-ingredient content against a certified reference standard, and LAL endotoxin screening validates sterility suitability for the aqueous injectable format. These controls are applied at the finished-product stage, after fill and seal, ensuring the stated 50mg/ml concentration and injectable safety profile are verified on the actual commercial unit rather than extrapolated from raw-material data alone.

Usage

Confirm the vial label reads Stanabol 50 — 50mg/ml — before preparing the injection; visually inspect the aqueous suspension and re-shake gently until uniform.
For a cutting-phase loading dose on day one, draw 1.0ml (50mg) using a sterile 1ml syringe with a 23–25g needle; this front-fills systemic concentration ahead of the every-other-day maintenance schedule.
Swab the vial stopper and the injection site with 70% isopropyl alcohol and allow to dry fully before needle entry.
Administer by intramuscular injection into the glute or lateral deltoid; rotate sites across the cutting phase to minimise localised irritation from the aqueous vehicle.
For 25mg doses in the final week or for female protocols, draw 0.5ml — this increment sits on a clearly visible syringe graduation, eliminating guesswork.
Log injection date, volume, and site after each administration; cross-reference with your lipid panel results (HDL by direct enzymatic assay at baseline and mid-cycle) to adjust dose or halt early if cardiovascular markers indicate accumulating suppression.

Warnings

Contraindications: Individuals with a confirmed diagnosis of prostate or breast carcinoma must not use this product. Severe hepatic impairment precludes use, as does pre-existing dyslipidaemia where HDL falls below 35 mg/dL. Known hypersensitivity to any constituent of the formulation is an absolute bar to use. Both pregnancy and lactation represent unconditional contraindications.

Side Effects: Androgenic adverse effects — including sebaceous-gland overactivity and thinning of scalp hair — are recognised risks in susceptible individuals. Hepatic stress accumulates in proportion to both dose and cycle duration, with transaminase elevation serving as the principal biochemical marker. Disruption of circulating lipid fractions, most notably a progressive decline in HDL, develops over the course of a cutting cycle. A proportion of users also report articular discomfort during caloric restriction, an effect attributed to diminished synovial fluid production.

Monitoring: Prior to commencing the cycle, a direct enzymatic HDL assay should be performed alongside a full liver enzyme screen encompassing ALT and AST, and a haematocrit measurement should be recorded as baseline. Lipid and hepatic markers must be reassessed at the midpoint of the cycle. Where the total cycle length surpasses six weeks, haematocrit should be re-evaluated to detect any erythrocytic accumulation.

PCT: Given stanozolol's brief plasma half-life, post-cycle therapy may be initiated as early as three to five days after the last injection. Restoration of hypothalamic-pituitary-gonadal axis function should be supported through a four-week course of a SERM — either tamoxifen or clomiphene is appropriate. Before PCT begins, any co-administered compounds carrying hepatotoxic potential should be withdrawn to facilitate HDL recovery without additional hepatic burden.

Frequently asked questions

Is injectable stanozolol at 50mg/ml effective specifically for a cutting cycle?: Yes — stanozolol is one of the most well-documented cutting-phase androgens because it does not aromatise to oestrogen, so no water retention blunts the visual outcome. At 50mg every other day, it supports nitrogen retention and SHBG suppression during a caloric deficit, preserving lean tissue while the body preferentially mobilises stored fat.
How do experienced athletes structure Stanabol 50 dosing across a cutting phase?: A common structure begins with a 50mg injection on day one as a loading dose, then 25–50mg every other day for weeks two through six. The 10ml vial provides enough volume to cover the full block. Dose is typically tapered or halted two to three days before cycle end to align with the compound's rapid plasma clearance.
What compounds pair well with Stanabol 50 for maximum definition without excess water retention?: Testosterone Propionate as a base keeps androgenic support high without oestrogen-driven fluid, while Trenbolone Acetate adds hardness through a non-aromatising mechanism. Both complement stanozolol's SHBG-suppressing action. All cardiovascular markers — particularly HDL measured by direct enzymatic assay — should be monitored throughout any multi-compound cutting stack.
Can Stanabol 50 be drawn accurately with an insulin syringe, and how does the 50mg/ml concentration help?: Yes. A standard 1ml insulin syringe graduated in 0.01ml units draws 0.5ml for a 25mg dose or 1.0ml for a 50mg dose from the 10ml vial — both increments sit on visible syringe markings without estimation. The 50mg/ml concentration is the lowest in this injectable stanozolol product group, offering the finest practical dose-step resolution for precise titration.
How should the Stanabol 50 10ml vial be stored after first use?: Store upright at 15–25°C away from direct light; refrigeration is not required but is acceptable. After first needle entry, use the vial within 28 days and inspect the suspension before each draw — re-shake gently to restore homogeneity if particles have settled. Discard if the suspension appears discoloured or if particulate matter does not disperse with agitation. (2) angle_used

Manufacturer

Stanabol 50 is packaged by British Dragon as a 10ml multi-use vial — a deliberate format choice that distinguishes it from single-ampoule presentations within the brand's injectable stanozolol range. The 10ml vial format is selected for cutting-cycle practitioners who require multiple measured draws across a four-to-ten-week protocol: the multi-dose presentation reduces per-cycle packaging waste and simplifies inventory management compared to sourcing equivalent total volume in individual ampoules. Each vial is filled under classified cleanroom conditions and sealed with a tamper-evident stopper, after which the finished unit enters a two-stage quality release sequence — HPLC potency quantification against a certified stanozolol reference standard followed by LAL endotoxin screening — before the batch is authorised for distribution. Fill volume is validated across the batch to confirm that draw volume consistency is maintained from the first syringe entry to the final draw, an important control point for a multi-use vial format where concentration uniformity across successive entries must match the 50mg/ml label declaration.

Product details

Brand	British Dragon
Active ingredient	stanozolol injection
Also known as	Winstrol Depot, injizierbares Stanozolol, Strombaject, Stanabol 50, British Dragon Winstrol Depot
Strength	50 mg
Form	Vial
Pack size	1 piece
Item number	INJ-STAN-BRD-50-023

Reviews

No reviews yet. Be the first to review this product.

Write a review

Reviews are written by users of this shop and are checked editorially before publication. Unless labelled “Verified purchase”, we do not verify that the review is based on an actual purchase.

Similar products

Strombaject 50mg/ml 10x1ml Ampoules by Balkan Pharmaceuticals

Established Brand

Strombaject 50mg/ml 10x1ml Ampullen by Balkan Pharmaceuticals

Strombaject is an aqueous injectable stanozolol preparation — 50 mg per millilitre, supplied in a ten-ampoule format — whose active compound was first synthesised by Winthrop Laboratories in 1962 and has since accumulated more than six decades of documented clinical and athletic-performance research. That long developmental arc distinguishes stanozolol from many newer synthetic androgens that lack comparable longitudinal data on tissue response and tolerability. Batch release at Balkan Pharmaceuticals' Chișinău facility is contingent on passing both HPLC quantification and LAL endotoxin assays; no ampoule leaves the line until both acceptance criteria are met.

€42.00

Stanobolin-50 50mg/ml 10x1ml Ampoules by BM Pharmaceuticals

High Concentration

Stanobolin-50 50mg/ml 10x1ml Ampullen by BM Pharmaceuticals

Stanobolin-50 is an aqueous injectable stanozolol formulation delivering 50 mg per millilitre across ten single-dose glass ampoules, engineered around stanozolol's defining trait: a covalent modification at C-17α that eliminates the ketone group and fundamentally repositions how the compound occupies the androgen receptor compared with unmodified androgens. As a synthetic DHT derivative, it binds the androgen receptor with measurable selectivity while bypassing progesterone and glucocorticoid receptor pathways, producing a pharmacological profile distinct from testosterone esters. Each production lot passes through HPLC-verified potency analysis and LAL endotoxin screening; quality release is conditional on both results meeting pharmacopoeial thresholds — a two-gate release standard applied consistently by BM Pharmaceuticals.

€42.00

Long-Acting Formula

StanoTrex 150mg/ml 10ml Vial by Concentrex Labs

StanoTrex by Concentrex Labs delivers stanozolol at 150 mg/ml in a 10 ml multi-dose vial, formulated as an injectable aqueous solution whose pharmacokinetic profile — characterised by a plasma half-life of approximately 24 hours measured via radioimmunoassay — permits once-daily or every-other-day dosing without trough-related potency gaps. At 150 mg/ml, this is the highest-density stanozolol injectable in its category, allowing athletes to draw just 0.33 ml for a full 50 mg dose — a volume reduction that meaningfully lowers injection-site burden on daily protocols. Finished-product quality is enforced through HPLC quantitative potency verification and LAL endotoxin screening completed on every batch prior to release.

€44.00

Winstrol Depot 50mg/ml 3x1ml Ampoules by Desma

GMP Standard

Winstrol Depot 50mg/ml 3x1ml Ampullen by Desma

Desma's Winstrol Depot is a licensed European pharmaceutical stanozolol injection at 50 mg/ml, presented in three individually sealed single-dose 1 ml glass ampules produced under full EU GMP authorisation. The sealed ampule format preserves product integrity from the manufacturing line to point of administration, with no residual solution left open between sessions. Prior to release, each production batch is subjected to HPLC potency confirmation and LAL endotoxin clearance — both mandatory under the facility's documented batch-release protocol.

€4.00

Stack it with

Pairs well with these products.

High Concentration

Quant-Equipoise 300mg/ml 10ml Vial by Beligas Pharmaceuticals

Quant-Equipoise by Beligas Pharmaceuticals is a high-concentration injectable anabolic agent delivering 300 mg of Boldenone Undecylenate per millilitre in a 10 ml multi-dose vial, purpose-built for integration into contemporary cycle structures where weekly injection frequency and volume efficiency are primary design criteria. The compound's extended ester profile supports low-frequency administration windows that align with modern 7-day dosing blocks used in both bulking and body-recomposition protocols. Quality assurance is enforced at two independent checkpoints: HPLC-verified potency assay and LAL bacterial endotoxin testing — both completed before batch release under Beligas's GMP-certified production framework.

€47.00

Bolden-250 250mg/ml 10x1ml Ampoules by BM Pharmaceuticals

Long-Acting Formula

Bolden-250 250mg/ml 10x1ml Ampullen by BM Pharmaceuticals

Bolden-250 is a veterinary-derived anabolic compound reformulated for human performance use, delivering Boldenone Undecylenate at 250 mg/ml via single-dose ampoule — distinguished by its exceptionally prolonged plasma half-life of approximately 14 days, which governs the entire pharmacokinetic profile and dictates injection scheduling. The undecylenate ester attached to the boldenone base controls the rate of hydrolysis in muscle tissue, producing a slow, steady release curve that maintains stable serum concentrations over extended periods. Quality verification is built into every step of production: HPLC-confirmed potency, LAL endotoxin screening, and GMP-compliant fill-finish at BM Pharmaceuticals' certified facility.

€48.00

Brand Quality

EquiTrex 350mg/ml 10ml Vial by Concentrex Labs

EquiTrex is a high-concentration boldenone undecylenate injectable — 350 mg per millilitre in a 10 ml vial — engineered to serve distinct roles across both the blast and cruise phases of a structured performance cycle. Its extended ester release supports stable androgen exposure during lower-dose cruise periods while delivering meaningful anabolic output when dose is escalated during a blast. Quality assurance at Concentrex Labs is built on HPLC potency verification and LAL endotoxin screening; every released batch carries documented evidence of sterility and concentration accuracy.

€52.00

Pro Choice

EQ 300 300mg/ml 10ml Vial by Dragon-Pharma

Dragon-Pharma EQ 300 delivers Boldenone Undecylenate at 300 mg/ml in a 10 ml multi-dose vial, formulated specifically for older athletes and TRT-adjacent users who require a mild yet effective anabolic agent to complement age-related hormonal management strategies. Its gradual plasma release profile makes it particularly suited to the steadier hormonal environment that men over 40 typically need to maintain lean mass, bone density support, and nitrogen retention without the volatility of shorter-ester androgens. Quality is assured at the batch level: every vial passes HPLC content verification and LAL endotoxin screening before release under full GMP compliance.

€44.00